Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...

As quantitative data replaced qualitative descriptions in the ads, and as information about severe adverse effects was ...

New AI software promises to make diagnosing dementia quicker and more accurate, helping doctors provide timely and effective ...

But Eli Lilly got there first. With the FDA's approval in early July of Kisunla, its new medicine for Alzheimer's developed ...

Boston University researchers developed an AI tool that accurately diagnoses 10 types of dementia, improving diagnosis ...

The studies underline differences between Eisai and Biogen’s treatment and Eli Lilly’s Alzheimer’s drug Kisunla (donanemab), which was approved on July 2. The Lilly drug exclusively targets ...

Alzheimer's Disease International estimates ... in the anti-amyloid category following the FDA approval of Eli Lilly's Kisunla (donanemab), which offers a reduced dosing frequency, meaning it ...

Eli Lilly (NYSE: LLY) has been on a winning streak recently, with shares popping up by roughly 60% since the start of 2024 ...

Lilly's success doesn't depend entirely on its obesity drug, though. Mounjaro, which is approved for type 2 diabetes, is the same drug under the hood as Zepbound and also has tremendous commercial ...

At the moment, there are two FDA-approved, antibody-based amyloid therapies for Alzheimer's – Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – which are given as infusions.

We recently compiled a list of the 12 Best Dividend Stocks For Steady Growth. In this article, we are going to take a look at ...

Recent notable innovations include two newly FDA-approved drugs to fight Alzheimer’s that work potentially forestalling ... Last month, the FDA approved Eli Lilly’s drug, Kisunla. And in February, ...